Miragen Therapeutics (MGEN) Receives Media Sentiment Rating of 0.11
Media stories about Miragen Therapeutics (NASDAQ:MGEN) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Miragen Therapeutics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.1120631207794 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
MGEN has been the subject of several research reports. Wedbush reaffirmed a “buy” rating and set a $19.00 price target on shares of Miragen Therapeutics in a research report on Wednesday, August 8th. Cann reissued a “buy” rating and issued a $19.00 target price on shares of Miragen Therapeutics in a report on Monday, August 6th. Zacks Investment Research raised shares of Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 target price for the company in a report on Wednesday, July 18th. Finally, ValuEngine raised shares of Miragen Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 6th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.86.
Miragen Therapeutics stock traded up $0.15 during midday trading on Monday, hitting $6.06. The stock had a trading volume of 71,800 shares, compared to its average volume of 201,845. The firm has a market capitalization of $180.83 million, a price-to-earnings ratio of -4.39 and a beta of 1.33. Miragen Therapeutics has a 52-week low of $5.01 and a 52-week high of $10.72. The company has a current ratio of 18.98, a quick ratio of 18.98 and a debt-to-equity ratio of 0.15.
About Miragen Therapeutics
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.
Recommended Story: Tariff
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.